Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Clarithromycin for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients With CD4 Counts <= 100 Cells/mm3
To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts \<= 100 cells/mm3.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Univ of Arizona / Health Science Ctr
Tucson, Arizona, United States
California Med Research Group
Fresno, California, United States
HIV Research Group
San Diego, California, United States
Saint Francis Mem Hosp
San Francisco, California, United States
Kaiser Permanente Med Ctr
San Francisco, California, United States
Santa Clara Valley Med Ctr
San Jose, California, United States
TheraFirst Med Ctrs Inc
Fort Lauderdale, Florida, United States
Dr Nelson Zide
Hollywood, Florida, United States
Infectious Disease Research Institute Inc
Tampa, Florida, United States
Indiana Univ Hosp
Indianapolis, Indiana, United States
Start Date
November 1, 1992
Primary Completion Date
November 1, 1994
Completion Date
November 1, 1994
Last Updated
January 16, 2015
Clarithromycin
DRUG
Lead Sponsor
Abbott
NCT06694805
NCT04142047
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330